Novel phospholipid-based topical formulations of tamoxifen: Evaluation for antipsoriatic activity using mouse-tail model

Pharmaceutical Development and Technology

Volumn 19, Issue 2, 2014, Pages 160-163

  Bhatia, Amit ^a   Singh, Bhupinder ^a   Wadhwa, Sheetu ^a   Raza, Kaisar ^a   Katare, Om Prakash ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Lecithin; Liposomes; Organogels; Orthokeratosis; Psoriasis; Skin

Indexed keywords

CARBOMER; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLOXAMER; TAMOXIFEN;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; FEMALE; FILM; GEL; HISTOPATHOLOGY; HYDROGEL; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; TAIL; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MODELS, ANIMAL; FEMALE; GELS; LECITHINS; LIPOSOMES; MICE; MICELLES; PHOSPHOLIPIDS; PSORIASIS; SKIN; TAMOXIFEN;

EID: 84874303629     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.763260     Document Type: Article

References (36)

1. Nguyen BL, Giambiagi N, Mayrand C, et al. Estrogen and progesterone receptors in the fetal and newborn vagina of guinea pig: biological, morphological: ultrastructural responses to tamoxifen and estradiol. Endocrinology 1986;119:978-88.
2. Pasqualini JR, Giambiagi N, Sumida C, et al. Biological responses of tamoxifen in the fetal and newborn vagina and uterus of the guinea-pig and in the R-27 mammary cancer cell line. J Steroid Biochem 1986;24:99-108.
3. Lewis JD, Chagpar AB, Shaughnessy EA, et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010;116:2307-15.
4. Cosco D, Paolino D, Cilurzo F, et al. Gemcitabine and tamoxifenloaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 2012;422:229-37.
5. Ferrari VD, Jirillo A. Psoriasis and tamoxifen therapy: a case report. Tumori 1996;82:262-3.
6. Stevens HP, Ostlere LS, Black CM, et al. Cyclical psoriatic arthritis responding to anti-oestrogen therapy. Br J Dermatol 1993;129: 458-60.
7. Boyd AS, King Jr LE. Tamoxifen-induced remission of psoriasis. J Am Acad Dermatol 1999;41:887-9.
8. Arun B, Hortobagyi, GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer 2002;9:15-32.
9. Murayama K, Kimura T, Tarutani M, et al. Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors. Oncogene 2007;26:4882-8.
10. Chan S. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol 2002;29:129-33.
11. Kramer R, Brown P. Should tamoxifen be used in breast cancer prevention?. Drug Saf 2004;27:979-89.
12. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008;31:127-41.
13. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116:131-9.
14. Ferguson SE, Soslow RA, Amsterdam A, Barakat RR. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006;101:322-6.
15. Valenzano Menada M, Costantini S, Moioli M, et al. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. Breast 2008; 17:631-6.
16. Bruno DL. Treatment of mastalgia with 4-hydroxy tamoxifen. 2004; WO/2004/054557(PCT/EP2003/015028).
17. Heard CM, Gallagher SJ. Preferential complexation between tamoxifen and borage oil/linolenic acid: transcutaneous delivery and NMR spectral modulation. Int J Pharm 2005;302:47-55.
18. Bhatia A, Singh B, Bhushan S, Katare OP. Tamoxifenencapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. Drug Dev Ind Pharm 2010;36: 350-4.
19. Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes: development, characterization and in vitro evaluation. J Pharm Pharm Sci 2004;7:252-9.
20. Bhatia A, Singh B, Katare OP. Tamoxifen in pluronic lecithin organogel: a novel topical approach for cancer treatment. AACR Centennial Conference on Translational Cancer Medicine: Technologies toTreatment; 2007 Nov 4-8; Suntec, Singapore;4:B24.
21. Bhatia A, Singh B, Katare OP. Topical tamoxifen: a novel approach in management of breast cancer. 12th Biennial IGCS Meeting; 2008 Oct 25-28; Bangkok, Thailand; 1095 (A-106-0006-01095).
22. Bhatia A, Singh B, Raza K, et al. Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis. J Drug Target 2012;20:544-50.
23. Shchipunov Yu A, Mezzasalma SA, Koper GJM, Hoffmann H. Lecithin organogel with new rheological and scaling behavior. J Phys Chem B 2001;105:10484-8.
24. Kumar R, Katare OP. Lecithin organogels as a potential phospholipid structured system for topical drug delivery: a review. AAPS PharmSciTech 2005;6:E298-310.
25. Raza K, Singh B, Mahajan A, et al. Evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target 2011;9:293-302.
26. Bosman B, Matthiesen T, Hess V, Friderichs E. A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. Skin Pharmacol 1992;5:41-8.
27. Hofbauer M, Dowd PM, Atkinson J, et al. Evaluation of a therapeutic concentration of dithranol in the mouse-tail test. Br J Dermatol 1988;118:85-9.
28. Bladon PT, Taylor M, Wood EJ, Cunliffe WJ. Effect of crude coal tar in the mouse-tail model of psoriasis. Arch Dermatol Res 1985;277:121-5.
29. Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol 2009;8:282-8.
30. Wrench R, Britten AZ. Evaluation of coal tar fractions for use in psoriasiform diseases using the mouse tail test. (II) Tar oil acids. Br J Dermatol 1975;92:575-9.
31. Cevc G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. Biochim Biophys Acta 2003; 1614:156-64.
32. Raza K, Katare OP, Setia A, et al. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nano-emulsomes. J Microencapsul 2012;717115. [Epub ahead of print]. doi:10.3109/02652048.2012. 717115.
33. Mitchell DJ, Winham BW. Micelles, vesicles and microemulsions. J Chem Soc Faraday Trans II 1981;77:601-29.
34. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration: transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-388.
35. Cevc G. Overcoming the skin barrier with artificial smart carriers of drugs. ACS Symp Ser 1999;728:70-86.
36. Lagzi I, Wang D, Kowalczyk B, Grzybowski BA. Vesicle-to-micelle oscillations and spatial patterns. Langmuir 2010;26:13770-2.